Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner
- 28 February 2006
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 42 (3), 422-426
- https://doi.org/10.1016/j.ejca.2005.11.009
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent MechanismClinical Cancer Research, 2005
- Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9International Journal of Cancer, 2004
- Cyclooxygenase-2 Promotes Human Cholangiocarcinoma GrowthCancer Research, 2004
- Celecoxib But Not Rofecoxib Inhibits the Growth of Transformed Cells in Vitro Clinical Cancer Research, 2004
- Cyclooxygenase 2: a molecular target for cancer prevention and treatmentTrends in Pharmacological Sciences, 2003
- NS‐398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell linesInternational Journal of Cancer, 2002
- COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxibThe FASEB Journal, 2001
- Control of mitosis by changes in the subcellular location of cyclin-B1–Cdk1 and Cdc25CCurrent Opinion in Cell Biology, 2000
- Mechanisms of G2 Arrest in Response to Overexpression of p53Molecular Biology of the Cell, 1999
- Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpointThe EMBO Journal, 1998